<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04387734</url>
  </required_header>
  <id_info>
    <org_study_id>RO-IIS-2019-20273</org_study_id>
    <nct_id>NCT04387734</nct_id>
  </id_info>
  <brief_title>Effects of Ocrevus in Relapsing Multiple Sclerosis</brief_title>
  <acronym>MOBILE-RMS</acronym>
  <official_title>Effects and Mechanisms of Ocrevus on Ambulatory Functions in People With Relapsing Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Georgia State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Multiple Sclerosis Center of Atlanta</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Georgia State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test if people with relapsing multiple sclerosis (RMS) can&#xD;
      improve ambulatory functions after one-year treatment with Ocrevus in comparison with&#xD;
      platform therapy. Sixty qualified individuals with RMS will be evenly assigned into two&#xD;
      groups: Ocrevus and Platform. Each group will receive the respective treatment following the&#xD;
      FDA regulations over the one-year course. Their ambulatory functions will be assessed five&#xD;
      times three months apart. In addition, they will receive brain MRI scans three times six&#xD;
      months apart. Their ambulatory functions and MRI measurements will be compared between groups&#xD;
      over time to fulfill the purposes of this study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 5, 2021</start_date>
  <completion_date type="Anticipated">September 2025</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dynamic Gait Stability</measure>
    <time_frame>12 months</time_frame>
    <description>To quantify dynamic balance of participants during level walking.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gait speed</measure>
    <time_frame>12 months</time_frame>
    <description>To quantify the distance covered per second.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Step length</measure>
    <time_frame>12 months</time_frame>
    <description>The length of the step.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Step width</measure>
    <time_frame>12 months</time_frame>
    <description>The width of the step.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Step time</measure>
    <time_frame>12 months</time_frame>
    <description>Time elapsed between heel-strike of the contralateral foot and the successive heel-strike of the ipsilateral foot</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cadence</measure>
    <time_frame>12 months</time_frame>
    <description>To quantify the number of steps taken within one minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stability index</measure>
    <time_frame>12 months</time_frame>
    <description>Sway index is to characterize the static postural control associated with three sensory systems in people with multiple sclerosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Swing index</measure>
    <time_frame>12 months</time_frame>
    <description>Swing index is another matrix measuring static balance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lower limb muscle strength</measure>
    <time_frame>12 months</time_frame>
    <description>The maximum voluntary muscle strength at bilateral knee and ankle joints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lower limb muscle activity</measure>
    <time_frame>12 months</time_frame>
    <description>The electrical activity of leg muscles during level walking</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Sclerosis Functional Composite</measure>
    <time_frame>12 months</time_frame>
    <description>The assessment of the disability status based on lower extremity function, upper extremity function, and cognitive function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expanded Disability Status Scale</measure>
    <time_frame>12 months</time_frame>
    <description>Another assessment of the level of disability in people with multiple sclerosis. The Expanded Disability Status Scale score ranges from 0 to 10 (in increments of 0.5). A smaller score indicates a lower level of disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total cerebral T2 lesion volume</measure>
    <time_frame>12 months</time_frame>
    <description>T2-weighted lesion volume has been used as a measure of disease progression in multiple sclerosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prospective falls</measure>
    <time_frame>12 months</time_frame>
    <description>The number of fall incidences occurred in everyday living, and the details of each fall (if any), including the date, environment, and possible causes will be recorded using a falls-questionnaire.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Relapsing Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Ocrevus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Platform therapies</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Platform therapies consist of the following injectable disease modification treatments: IFNb-1a, IFNb-1b, and glatiramer acetate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ocrelizumab</intervention_name>
    <description>Ocrevus will be administered following the FDA's regulations.</description>
    <arm_group_label>Ocrevus</arm_group_label>
    <other_name>Ocrevus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Platform</intervention_name>
    <description>The applications of the platform DMTs will follow the FDA-approved regulations.</description>
    <arm_group_label>Platform therapies</arm_group_label>
    <other_name>Other injectable Disease Modification Treatments</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ability to provide written, informed consent and to be compliant with the schedule of&#xD;
             protocol assessments;&#xD;
&#xD;
          2. Ages 18-65 years old at screening;&#xD;
&#xD;
          3. Clinically confirmed active, relapsing forms of MS (RMS) based on the revised McDonald&#xD;
             criteria;&#xD;
&#xD;
          4. Can walk at least 25 feet independently with or without assistive device at screening&#xD;
             (or the Expanded Disability Status Scale between 1 and 6.5);&#xD;
&#xD;
          5. Can stand independently for at least 30 seconds;&#xD;
&#xD;
          6. Not pregnant at screening and throughout the study;&#xD;
&#xD;
          7. No other neurological conditions and recent musculoskeletal injuries;&#xD;
&#xD;
          8. Can read and understand English;&#xD;
&#xD;
          9. No significant cognitive impairment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of other types of MS at screening such as, primary-progressive MS);&#xD;
&#xD;
          2. Inability to complete an MRI (contraindications for MRI include but are not limited to&#xD;
             claustrophobia, body mass greater than 140 kg, pacemaker, cochlear implants, presence&#xD;
             of foreign substances in the eye, intracranial vascular clips, surgery within 6 weeks&#xD;
             of entry into the study, coronary stent implanted within 8 weeks before the time of&#xD;
             the intended MRI, etc);&#xD;
&#xD;
          3. Patients with an active hepatitis B virus (HBV) infection;&#xD;
&#xD;
          4. Have a life-threatening allergic reaction to ocrelizumab or any of its ingredients in&#xD;
             the past;&#xD;
&#xD;
          5. Hypersensitive to any of the ingredients of ocrelizumab;&#xD;
&#xD;
          6. Do not understand English.&#xD;
&#xD;
             Exclusions related to general health&#xD;
&#xD;
          7. Pregnancy or lactation;&#xD;
&#xD;
          8. Have any other known neurological diseases which may mimic MS including but not&#xD;
             limited to: Neuromyelitis optica, Lyme disease, untreated vitamin B12 deficiency,&#xD;
             neurosarcoidosis, and cerebrovascular disorders;&#xD;
&#xD;
          9. Suffering from coexisting psychiatric disorders, neurological disorders, or severe&#xD;
             medical illness;&#xD;
&#xD;
         10. Current severe depression and/or suicidal ideation;&#xD;
&#xD;
         11. Significant cognitive impairment (Montreal Cognitive Assessment score &lt; 24);&#xD;
&#xD;
         12. New onset, unstable orthopedic comorbid diagnoses (within 3 months and uncontrolled);&#xD;
&#xD;
         13. History or currently active primary or secondary immunodeficiency;&#xD;
&#xD;
         14. Receipt of a live vaccine within 6 weeks prior to baseline;&#xD;
&#xD;
         15. Skin is allergic to transparent double-side tapes;&#xD;
&#xD;
         16. Any concomitant disease that may require chronic treatment with systemic&#xD;
             corticosteroids or immunosuppressants during the course of the study;&#xD;
&#xD;
         17. History or currently active primary or secondary immunodeficiency;&#xD;
&#xD;
         18. Lack of peripheral venous access;&#xD;
&#xD;
         19. History of severe allergic or anaphylactic reactions to humanized or murine monoclonal&#xD;
             antibodies;&#xD;
&#xD;
         20. Significant or uncontrolled somatic disease or any other significant disease that may&#xD;
             preclude patient from participating in the study;&#xD;
&#xD;
         21. Congestive heart failure (NYHA III or IV functional severity);&#xD;
&#xD;
         22. Known active bacterial, viral, fungal, mycobacterial infection or other infection,&#xD;
             excluding fungal infection of nail beds;&#xD;
&#xD;
         23. Infection requiring hospitalization or treatment with i.v. antibiotics within 4 weeks&#xD;
             prior to baseline visit or oral antibiotics within 2 weeks prior to baseline visit;&#xD;
&#xD;
         24. History or known presence of recurrent or chronic infection (e.g., hepatitis B or C,&#xD;
             HIV, syphilis, tuberculosis);&#xD;
&#xD;
         25. History of progressive multifocal leukoencephalopathy (PML);&#xD;
&#xD;
         26. History of malignancy, including solid tumors and hematological malignancies, except&#xD;
             basal cell carcinoma, in situ squamous cell carcinoma of the skin, and in situ&#xD;
             carcinoma of the cervix of the uterus that have been previously completely excised&#xD;
             with documented, clear margins;&#xD;
&#xD;
         27. History of alcohol or drug abuse within 24 weeks prior to baseline;&#xD;
&#xD;
         28. History or laboratory evidence of coagulation disorders;&#xD;
&#xD;
             Exclusions related to medications&#xD;
&#xD;
         29. Receipt of a live vaccine within 6 weeks prior to baseline;&#xD;
&#xD;
         30. Treatment with any investigational agent within 24 weeks of screening (Visit 1) or&#xD;
             five half-lives of the investigational drug (whichever is longer);&#xD;
&#xD;
         31. Contraindications to or intolerance of oral or intravenous corticosteroids, including&#xD;
             methylprednisolone administered intravenous, according to the country label,&#xD;
             including:&#xD;
&#xD;
               1. Psychosis not yet controlled by a treatment;&#xD;
&#xD;
               2. Hypersensitivity to any of the constituents;&#xD;
&#xD;
         32. Treatment with dalfamipridine (Ampyra®) unless on stable dose for ≥ 30 days prior to&#xD;
             screening. Patients should remain on stable doses throughout the 52-week treatment&#xD;
             period;&#xD;
&#xD;
         33. Previous treatment with B-cell targeted therapies (i.e. rituximab, ocrelizumab,&#xD;
             atacicept, belimumab or ofatumumab);&#xD;
&#xD;
         34. Systemic corticosteroid therapy within 4 weeks prior to screening;&#xD;
&#xD;
         35. Any previous treatment with alemtuzumab (Campath), anti-CD4, cladribine, mitoxantrone,&#xD;
             daclizumab, BG12, teriflunomide, laquinimod, total body irradiation or bone marrow&#xD;
             transplantation;&#xD;
&#xD;
         36. Treatment with cyclophosphamide, azathioprine, mycophenolate mofetil (MMF),&#xD;
             cyclosporine, methotrexate, or natalizumab within 24 months prior to screening;&#xD;
&#xD;
         37. Treatment with intravenous immunoglobulin within 12 weeks prior to baseline.&#xD;
&#xD;
             Exclusions related to motor function&#xD;
&#xD;
         38. Cannot walk at least 25 feet and stand at least 30 seconds independently;&#xD;
&#xD;
         39. Weak or blind vision may impair their ability of walking;&#xD;
&#xD;
             Exclusions related to musculoskeletal, cardiovascular, and orthopedic condition&#xD;
&#xD;
         40. Broken bones as an adult in the past year;&#xD;
&#xD;
         41. Have received neurological treatment, such as Botox, in the past six months;&#xD;
&#xD;
         42. Heart attack, angioplasty, or coronary artery bypass graft in the past six months;&#xD;
&#xD;
         43. Congestive heart failure (NYHA III or IV functional severity);&#xD;
&#xD;
         44. Surgery on back, hip, shoulder, or total joint replacement of hip or knee joint less&#xD;
             than two years ago;&#xD;
&#xD;
         45. Respiratory conditions (lung cancer, bronchitis, emphysema, asthma, shortness of&#xD;
             breath) not under regular medical care or the patient is medically unstable.&#xD;
&#xD;
             Exclusions related to laboratory findings&#xD;
&#xD;
         46. Positive serum β hCG measured at screening;&#xD;
&#xD;
         47. Positive screening tests for hepatitis B (hepatitis B surface antigen [HBsAg]&#xD;
             positive, or positive hepatitis B core antibody [total HBcAb] confirmed by a positive&#xD;
             viral deoxyribonucleic acid [DNA] polymerase chain reaction [PCR]) or hepatitis C&#xD;
             (HepCAb);&#xD;
&#xD;
         48. Positive rapid plasma reagin (RPR);&#xD;
&#xD;
         49. CD4 count &lt; 300/μL;&#xD;
&#xD;
         50. AST/SGOT or ALT/SGPT ≥ 2.0 Upper Limit of Normal (ULN);&#xD;
&#xD;
         51. Platelet count &lt;100,000/μL (&lt;100 x 109/L);&#xD;
&#xD;
         52. Levels of serum IgG &lt;5.65 g/L;&#xD;
&#xD;
         53. Levels of serum IgM &lt; 0.55 g/L;&#xD;
&#xD;
         54. Total neutrophil count &lt;1.5 x 103/μL.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Feng Yang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Georgia State University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Feng Yang, PhD</last_name>
    <phone>404-413-8357</phone>
    <email>fyang@gsu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Georgia State University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feng yang, PhD</last_name>
      <phone>404-413-8357</phone>
      <email>fyang@gsu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Multiple Sclerosis Center of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30327</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joash Lazarus, MD</last_name>
      <phone>404-351-0205</phone>
      <email>jtlazarus@mscatl.org</email>
    </contact>
    <investigator>
      <last_name>Joash Lazarus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 11, 2020</study_first_submitted>
  <study_first_submitted_qc>May 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2020</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Georgia State University</investigator_affiliation>
    <investigator_full_name>Feng Yang, PhD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Mobility; Fall risk; Balance; Multiple sclerosis; T2LV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ocrelizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

